- All cancer types
- Brain tumor
- Breast cancer
- Cervical cancer
- Childhood cancer
- Colon cancer
- Endometrial cancer
- Kidney cancer
- Lung cancer
- Multiple myeloma
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Skin cancer
- Stomach cancer
- Testicular cancer
What do patients know and believe about immunotherapy? CareAcross conducted an extensive study collecting responses from 5,589 cancer patients.
Clinical Trials are the cornerstone of research activities for new ways to treat cancer. Unfortunately, many barriers prevent patients from learning about, and participating in clinical trials. Our Chief Medical Officer weighs in.
Every year, the largest cancer conference delivers new research and hope for cancer patients worldwide - and this year's is no exception. In this article we provide details on a significant breast cancer finding, straight from Chicago.
Fiona Nielsen is working 24/7 to promote efficient and ethical human genomic data sharing. She recently published a very interesting article on the need to modernise the "consent form".
Professor Håkan Mellstedt is a medical oncologist at the Cancer Center Karolinska in Sweden, with extensive clinical and academic experience. In this article, Prof. Mellstedt, also a member of our Scientific Committee, explains the basics of immunotherapy and key research being conducted across cancer types.
A session at the 2014 ASCO meeting focused on targeted adenocarcinoma treatment for specific genetic mutations-a promising option for some lung cancer patients.
At the European Lung Cancer Conference, new information on lung cancer incidence, key factors and genetic mutations were discussed. We present the highlights.
Statins are normally used to lower cholesterol (which is seemingly irrelevant to prostate cancer). However, cholesterol controls pathways related to prostate cancer cells’ survival. In article, our Chief Medical Officer describes the potential benefit to prostate cancer patients, based on two recently published studies.
Adenocarcinoma is the most common type of non-small cell lung cancer. Our Chief Medical Officer explains the benefits from the latest research on targeted drugs.